Phase 2 Completed N=22 Randomized Quadruple-blind Treatment

Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis

uveitis · macular edema · Uveitis, Posterior · Uveitis, Anterior

Source: ClinicalTrials.gov NCT02255032 ↗

Enrolled (actual)

Serious AEs

4.6%

Results posted

Feb 2021

Primary outcomePrimary: Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following Uveitis — -164.44; -78.20 Microns — p=0.0017

Summary

The study is designed to evaluate the safety and efficacy of triamcinolone acetonide, CLS-TA, in subjects with macular edema following non-infectious uveitis. A single suprachoroidal injection of one of two doses of CLS-TA will each be evaluated in subjects with macular edema following non-infectious uveitis.

Outcome Measures

Outcome	Result	p-value
PRIMARY Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following Uveitis	-164.44; -78.20	0.0017 sig

Eligibility Criteria

Inclusion Criteria

diagnosis of noninfectious uveitis
diagnosis of macular edema associated with noninfectious uveitis

Exclusion Criteria

any ocular trauma within the immediate 6 months prior to treatment
any photocoagulation or cryotherapy in the 6 months prior to treatment
any IVT injection of anti-VEGF treatment in the 2 months prior to treatment
any eye diseases other than uveitis and ME that could compromise central visual acuity
any previous suprachoroidal injection of triamcinolone acetonide in the study eye

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02255032). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.